Professor Jeremy Everett

Professor Jeremy Everett BSc, PhD, FRSC, CChem

Professor of Pharmaceutical Technologies

Key details

Professor Jeremy R Everett
BSc, PhD, FRSC, CChem

Professor of Pharmaceutical Technologies


Professor Jeremy Everett is Professor of Pharmaceutical Technologies in the Department of Pharmaceutical, Chemical & Environmental Sciences within the School of Science.

Professor Everett's main research focus is in metabolic profiling, also known as metabonomics or metabolomics. He has a particular interest in studying the consequences of genetic mutations on metabolic phenotypes and on the interplay between the genome and microbiome. He co-conceived, and named and defined metabonomics together with Professor Jeremy Nicholson (Imperial College, London), with whom he has a long-standing collaboration. He is a co-discoverer of pharmacometabonomics: which is the ability to predict the effects of drugs prior to dosing via metabolic profiling, and he is a co-inventor on a granted patent on pharmacometabonomics. He is a Visiting Professor in the Department of Surgery and Cancer at Imperial College. He is also currently the Acting Director of the Singapore Phenome Centre and is a scientific consultant and a Visiting Professor at the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore.

Professor Everett is a co-leader of the Medway Metabonomics Group (MMRG) together with Dr Ruey-Leng Loo from the School of Pharmacy.

Professor Everett is the author of nearly 100 publications and reviews and a co-inventor on 3 patents. He has an H-index of 28 and has been cited in the literature over 4,000 times, with his top 4 papers each cited over 400 times.

Professor Everett consults for both major pharmaceutical and small biotech and research institutes on drug discovery. He is also a consultant for a New York law firm on pharmaceutical patents.

Prior to his current position, Professor Everett held a variety of drug discovery technology leadership positions at Pfizer, and before that, SmithKline Beecham and Beecham Research Laboratories. These positions included responsibilities for analytical sciences, automated purification, biobanking, chemoinformatics, computational chemistry, ligand-based drug design, curation, management and provision of the compound screening file, data support and management, lead generation by high throughput screening, compound library design and production, indications discovery, structural biology, structure-based drug design and drug target analysis.

Professor Everett received both his BSc in chemistry and PhD in physical organic chemistry from Nottingham University. He was a Post-doctoral Fellow at McMaster University in Hamilton, Ontario, and a Research Associate at McGill University, Montréal.

Responsibilities within the university

  • University representative to the Heads of Chemistry UK (HCUK) at the Royal Society of Chemistry

Course participation

  • Advanced Instrumental Analysis
  • Applied Plant Science
  • Chemometrics and Informatics
  • Computational Chemistry
  • Drug Discovery and Medicinal Chemistry
  • Medicinal Chemistry and Therapeutics
  • Open Course for Chemists
  • Pharmaceutics
  • Pharmaceutical Analysis & Testing
  • Pharmaceutical Product Development and Manufacture
  • Research and Professional Skills
  • Research Methods and Data Management
  • Special Topics in Chemistry

MPhil/PhD supervision

  • Mohamed Abdelghany
  • Dorna Varshavi

Recognition

  • Fellow of the Royal Society of Chemistry (FRSC)
  • Chartered Chemist (CChem)
  • Visiting Professor, Department of Surgery and Cancer, Imperial College, London
  • Visiting Professor Lee Kong Chian School of Medicine, Nanyang Technological University
  • Member of the American Chemical Society
  • Fellow of the Higher Education Academy

Research / Scholarly interests

Professor Jeremy Everett's research covers metabonomics, pharmacometabonomics, with a particular focus on the relationship between genetic mutation and metabolic phenotype. He has 100 publications and patents including two, landmark publications in PNAS and Nature on the discovery of pharmacometabonomics. Web of Science Impact Factor: h-index = 28, with over 4,000 citations.

Other

Patents
  • Clayton, T.A., Everett, J.R., Lindon, J.C., and Nicholson, J.K. Metabolic Phenotyping. WO 03/107270 A2, published 24 December 2003
  • Everett, J. et al. Molecular Markers of Oxidative Stress. PC32039, filed November 2003 ACCESSION NUMBER:2005:493754 HCAPLUS PRIORITY APPLN. INFO.: GB 2003-27743 A20031128; US 2004-558937 P20040402.

Recent publications

Article

Varshavi, Dorna , Varshavi, Dorsa, Veselkov, Kirill, McCarthy, Nicola , Keun, Hector C. , Everett, Jeremy R. , Horizon Discovery (2020), Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines, Springer. In: , , , . Springer, Metabolomics ISSN: 1573-3882 (Print), 1573-3890 (Online) (doi: https://doi.org/10.1007/s11306-020-01674-2) Published.

Veeravalli, Sunil , Phillips, Ian R., Freire, Rafael T., Varshavi, Dorsa , Everett, Jeremy R. , Shephard, Elizabeth A. (2020), Flavin-Containing Monooxygenase 1 (FMO1) catalyzes the production of taurine from hypotaurine, American Society for Pharmacology and Experimental Therapeutics (ASPET). In: , , , . American Society for Pharmacology and Experimental Therapeutics (ASPET), Drug Metabolism and Disposition ISSN: 0090-9556 (Print), 1521-009X (Online) (doi: https://doi.org/10.1124/dmd.119.089995) Published NB Item availability restricted.

Everett, Jeremy R. , Holmes, Elaine, Veselkov, Kirill A., Lindon, John C. , Nicholson, Jeremy K. (2019), A unified conceptual framework for metabolic phenotyping in diagnosis and prognosis, Elsevier. In: , , , . Elsevier, Trends in Pharmacological Sciences pp. 763-773 ISSN: 0165-6147 (Print), 1873-3735 (Online) (doi: https://doi.org/10.1016/j.tips.2019.08.004) Published.

Scott, Flora H. , Varshavi, Dorsa, Veeravalli, Sunil, Phillips, Ian R. , Veselkov, Kirill , Strittmatter, Nicole , Takats, Zoltan , Shephard, Elizabeth A. , Everett, Jeremy R. (2018), Metabolic biomarkers of ageing in C57BL/6J wild-type and flavin-containing monooxygenase 5 (FMO5)-knockout mice, Frontiers Media. In: , , , . Frontiers Media, Frontiers in Molecular Biosciences 2296-889X (Online) (doi: https://doi.org/10.3389/fmolb.2018.00028) Published.

Book section

Everett, Jeremy and , (2019), Pharmacometabonomics: the prediction of drug effects using metabolic profiling, Springer. In: , , In: James E. Barrett, Clive P. Page, Martin C. Michel (eds.), Concepts and Principles of Pharmacology: 100 Years of the Handbook of Experimental Pharmacolog. Springer, Cham, Switzerland (1st) pp. 263-300 ISBN: 9783030353612 (doi: https://doi.org/10.1007/164_2019_316) Published NB Item availability restricted.

Everett, Jeremy and , (2018), Applications of metabolic phenotyping in pharmaceutical research and development, Elsevier. In: , , In: John C. Lindon, Jeremy K. Nicholson, Elaine Holmes (eds.), The Handbook of Metabolic Phenotypin. Elsevier, pp. 407-448 ISBN: 9780128122938 (doi: https://www.elsevier.com/books/the-handbook-of-metabolic-phenotyping/lindon/978-0-12-812293-8) Published NB Item availability restricted.

Conference item

Said, Mohamed , Thompson, Elinor, Everett, Jeremy (2019), Metabolic ageing in the C. elegans worm and modulation by genetic knock-out, phototherapy and drugs, The Genetics Society. In: UK C.elegans meeting, 16th September 2019, Imperial College London, Sir Alexander Fleming Building, Imperial College Rd, London, UK , UK C.elegans Meeting London 16 September 2019 Proceeding. The Genetics Society, (doi: http://p35-preview.runhosting.com/londonelegans2019.co.uk/) Unpublished NB Item availability restricted.